

Minutes of the HPRA Leadership Team

Licensing and regulation section

- Friday 03 October 2025 at 9.30am
- Hybrid Teams call and CEO's meeting room 3rd floor

Chair	Present	Apologies
Ms R. Purcell, Deputy Chief Executive	Mr S. d'Art, Director of ICT and Business Services	Dr L. Nolan, Chief Executive
	Dr N. MacAleenan, Director of Medical Devices	Dr D. Murphy, Director of Veterinary Science*
	Ms S. Curran, Director of Human Products Monitoring	Dr F. Lonsdale, Director of Human Medicines*
	Ms G. Power, Director of Compliance	
	Ms. N. Riggs, Director of Human Resources and Development	

Minutes taken by Minutes taken by Ms K. Murphy, Secretary to the Committees
Please note that certain information, such as personal data, confidential/commercially sensitive information, and pending prosecutions may have been removed from these minutes.

*Approved via written procedure

**Attended part of the meeting

1 ADOPTION OF THE AGENDA

The meeting adopted the agenda.

2 DECLARATIONS OF INTEREST

There was nothing to report.

3 ADOPTION OF THE MINUTES OF THE LAST MEETING

The minutes of the meeting of 26 September 2025 were adopted and signed.

4 MATTERS ARISING

There was nothing to report.

5 PUBLIC HEALTH ISSUES

5.1 Counterfeit tirzepatide injection pens

HLT were informed of a recent detention of counterfeit tirzepatide injection, two of the three of which were found to contain traces of insulin. A rapid alert has been issued, follow-ups are ongoing and next steps are under consideration.

6 PRODUCT ISSUES

There was nothing to report.

7 REJECTIONS, SUSPENSIONS AND REVOCATIONS

There was nothing to report.

8 LICENSING TABLES

The relevant tables submitted were approved.

9 AOB

9.1 Sodium Valproate inquiry

Further discussions were had in relation to the HPRA's submission to the sodium valproate inquiry.

9.2 2026 fees

HLT agreed the proposed uplift of 2.5% in HPRA fees for 2026.